EVX Ventures

EVX Ventures is a global venture capital firm established in 2015 and headquartered in Singapore. The firm focuses on building, incubating, and investing in early-stage biotechnology companies. It specializes in disruptive therapeutic platform technologies and novel therapeutic modalities, aiming to redefine future therapeutics. By investing in innovative global technologies, EVX Ventures seeks to advance the biotech industry and foster the development of transformative healthcare solutions.

XQ Lin

Chairman and Managing Director

XiangQian (XQ) Lin

Founder, Managing Director and Chairman

Kelly Wong

Analyst

2 past transactions

Carmine Therapeutics

Series A in 2022
Carmine Therapeutics, established in 2019 and headquartered in Singapore, specializes in gene therapy. It produces extracellular vesicles from red blood cells as a non-viral, re-dosable gene delivery vehicle, addressing challenges posed by traditional viral-based therapies such as immunogenicity, limited transgene capacity, and manufacturing complexities. The company focuses on developing next-generation gene therapies for hematology, oncology, and immunology.

Nuevocor

Series A in 2021
Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in patients with cardiovascular diseases. The firm specifically targets genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor aims to provide innovative solutions that enable healthcare professionals to effectively treat these conditions and improve heart health in affected individuals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.